ERIC I. RICHMAN - 20 Sep 2022 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
20 Sep 2022
Transactions value $
$0
Form type
4
Filing time
22 Sep 2022, 16:14:52 UTC
Previous filing
12 Sep 2022
Next filing
22 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +329,400 $0 329,400 20 Sep 2022 Common Stock 329,400 $3.5 Direct F1
transaction GANX Restricted Stock Units Award $0 +54,900 $0 54,900 20 Sep 2022 Common Stock 54,900 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest fully on September 20, 2023, subject to Reporting Person's continuous service through such date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3 The RSUs shall vest fully on September 20, 2023, subject to Reporting Person's continuous service through such date.